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Synopsis  25 
Objectives: The goal of the present study was to obtain a comprehensive overview of 26 
the bacteriostatic and bactericidal effects of six commonly used antibiotics on 27 
planktonic as well as on sessile Burkholderia cepacia complex cells.  28 
29 
30 
31 
Methods: The bacteriostatic and bactericidal activities of ceftazidime, ciprofloxacin, 
meropenem, minocycline, tobramycin and trimethoprim-sulfamethoxazole were 
determined on 38 B. cepacia complex strains. MICs and minimal biofilm inhibitory 
concentrations (MBICs) were determined using a traditional broth microdilution 32 
method and a novel resazurin-based viability staining, respectively. The bactericidal 33 
effects of the investigated antibiotics (using antibiotic concentrations corresponding to 34 
10 x MIC; except for tobramycin, for which a final concentration of 4 x MIC was tested) 35 
on stationary phase planktonic cultures and on 24 h old biofilms were evaluated using 
conventional plate count methods. 
36 
37 
38 
39 
40 
41 
42 
Results: Our results confirm the innate resistance of B. cepacia complex organisms 
against six first-line antibiotics used to treat infected CF patients. All antibiotics 
showed similar bacteriostatic activities against exponentially growing B. cepacia 
complex planktonic cells and freshly adhered sessile cells (4 h). In addition, most of 
the antibiotics showed similar bactericidal effects on stationary phase planktonic 
cultures and on young and older biofilms. 43 
44 
45 
46 
47 
48 
49 
Conclusions: Despite the general assumption that sessile cells show a decreased 
susceptibility to antibiotics, our data indicate similar bacteriostatic and bactericidal 
activity of six selected antibiotics against planktonic and sessile B. cepacia complex 
bacteria. 
 
 
 
Introduction 50 
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Burkholderia cepacia complex bacteria are opportunistic pathogens that can cause 
severe infections in patients with cystic fibrosis (CF) or chronic granulomatous 
disease (CGD) and in immunocompromised individuals. 1 The taxonomy of the genus 
Burkholderia has undergone several major revisions over the last decades. In the 
mid-1990s, “Burkholderia cepacia” strains were demonstrated to belong to at least 
five distinct species, which were collectively referred to as the B. cepacia complex. 2 
Further taxonomic analyses revealed that even more species were present within the 
B. cepacia complex and currently 17 B. cepacia complex species have been 
described. 2-5   Except for Burkholderia ubonensis, all of these species have been 
isolated from sputum of CF patients, 4,5 with Burkholderia cenocepacia and 
Burkholderia multivorans being predominant. 6 
Infections with B. cepacia complex bacteria in CF patients are often correlated with 
increased morbidity and mortality and the innate resistance of these organisms to a 
broad range of antibiotics complicates the treatment of infected patients. 
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7,8 This 
panresistance is caused by various mechanisms, including limited permeability, 
changes in lipopolysaccharide structure and the presence of several multidrug efflux 
pumps, inducible chromosomal beta-lactamases and altered penicillin-binding 
proteins. 9 In addition, in vitro biofilm formation has been described for multiple B. 
cepacia complex strains and this may contribute to their ability to survive in the CF 
lung environment by providing additional protection from antibiotics. 1,10,11 
Treatment of B. cepacia complex infected patients should preferably be based on the 
results of susceptibility tests and often includes combination therapy with two or three 
antibiotics showing synergistic activity. 
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7,12,13 In vitro susceptibility studies on B. 
cepacia complex strains show that breakpoint concentrations of ceftazidime, 
 
ciprofloxacin, meropenem, tetracyclines (doxycycline or minocycline) or high doses of 
tobramycin have a bacteriostatic activity against a considerable fraction of these 
strains. 
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8,12,14 Consequently, these antibiotics are often used to treat B. cepacia 
complex infected CF patients. In addition, co-trimoxazole (i.e. a combination of 
trimethoprim and sulfamethoxazole) is still frequently used in the treatment of chronic 
B. cepacia complex infections, although susceptibility testing of these complementary 
antibiotics revealed a poor activity against many B. cepacia complex strains. 
79 
80 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
13,15 
Often, antibiotics showing a good in vitro activity fail in vivo. This failure is partly due 
to differences between the in vitro test conditions and the actual in vivo challenge. 
For example, in conventional susceptibility testing and multiple combination 
bactericidal testing (MCBT), planktonic cultures with actively-multiplying cells are 
used, 12,16 but these may poorly represent susceptibility of stationary phase or slow-
growing cultures. 17,18 In addition, bacterial cells may reside in biofilms. These 
consortia of microbial cells are embedded in a matrix of self-produced extracellular 
components and they are considered to exhibit an increased resistance compared to 
their free-floating planktonic counterparts. 19 Finally, inactivation of antibiotics in 
sputum or insufficient antibiotic concentrations in sputum, might also contribute to a 
poor in vivo activity despite a satisfactory in vitro activity. 20 
The first objective of the present study was to evaluate the growth inhibitory effect of 
six antibiotics (ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and 
trimethoprim-sulfamethoxazole) on planktonic as well as on freshly adhered sessile 95 
cells (4 h) of all B. cepacia complex species. The second objective was to examine 96 
the bactericidal effect of these antibiotics on stationary phase planktonic cultures and 97 
to compare this to the bactericidal effect observed for biofilms. 98 
99  
 
Materials and methods 100 
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Strains and culture conditions 
The following strains were used: Burkholderia cepacia LMG 1222T and LMG 18821; 
B. multivorans LMG 18822, LMG 18825, LMG 13010T and LMG 17588; B. 
cenocepacia LMG 16656T, LMG 18828, LMG 18829 and LMG 18830; Burkholderia 
stabilis LMG 14294T and LMG 14086; Burkholderia vietnamiensis LMG 18835 and 
LMG 10929T; Burkholderia dolosa LMG 18941 and LMG 18943T; Burkholderia 
ambifaria LMG 19182T and LMG 19467; Burkholderia anthina LMG 20980T and LMG 
20983; Burkholderia pyrrocinia LMG 14191T and LMG 21824; B. ubonensis LMG 
20358T and LMG 24263; Burkholderia latens LMG 24064T and R-11768; 
Burkholderia diffusa LMG 24065T and LMG 24266; Burkholderia arboris LMG 24066T 
and R-132; Burkholderia seminalis LMG 24067T and LMG 24272; Burkholderia 
metallica LMG 24068T and R-2712; Burkholderia lata LMG 6992 and R-9940; 
Burkholderia contaminans LMG 16227 and R-12710.  All strains were obtained from 
the BCCM/LMG Bacteria Collection (Ghent, Belgium) or were kindly provided by Dr. 
P. Vandamme (Ghent University, Belgium). Pseudomonas aeruginosa ATCC 27853 
and Escherichia coli ATCC 25922 were included as control strains and were obtained 
from the ATCC collection (Manassas, VA, USA). Cells were stored at -80°C using 
Microbank vials (Prolab Diagnostics, Richmond Hill, ON, Canada) and were 
subcultured twice on Mueller Hinton Agar (MHA; Oxoid, Hampshire, UK) before they 
were used in any experiment.  All cultures were incubated aerobically at 37°C. 
 
Antibiotics 
Ceftazidime, ciprofloxacin, tobramycin and sulfamethoxazole were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). Minocycline and trimethoprim were obtained 
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from Certa (Braine-l’Alleud, Belgium) and meropenem was obtained from 
AstraZeneca (London, UK). 
 
Determination of the MIC 
MICs were determined in duplo according to the EUCAST broth microdilution 
protocol using flat-bottomed 96-well microtitre plates (TPP, Trasadingen, 130 
Switzerland). 21 The range of antibiotic concentrations was from 0.25 mg/L to 128 131 
mg/L for ceftazidime, ciprofloxacin, meropenem and minocycline; for tobramycin, 132 
higher concentrations were tested (between 2 mg/L and 1024 mg/L). Trimethoprim-133 
sulfamethoxazole concentrations tested were between 0.25-4.75 mg/L and 128-2432 134 
mg/L. The inoculum was standardized at appr. 5 x 105 cfu/mL.  The plates were 
incubated at 37°C for 20 h and the optical density was determined at 590 nm using a 
135 
136 
multilabel microtitre plate reader (Victor2, Perkin Elmer LAS, Waltham, MA, USA). 
The lowest concentration of antibiotic for which a similar optical density was 
137 
138 
observed in the inoculated and blank wells was recorded as the MIC. The quality of 
the test results was monitored using two control strains (P. aeruginosa ATCC 27853 
and E. coli ATCC 25922). CLSI-interpretative criteria for MIC testing of non-
139 
140 
141 
Enterobacteriaceae were used to evaluate the MIC results. 16 An adapted breakpoint 142 
MIC of 256 mg/L was also included for tobramycin. 14  143 
144 
145 
 
Determination of the minimal biofilm inhibitory concentration (MBIC) 
In order to determine the growth inhibitory effects of the antibiotics on freshly 146 
adhered sessile cells, a novel non-standard method using a resazurin-based viability 147 
staining was applied. 22 The MBIC was defined as the minimum concentration of 148 
antibiotic necessary to prevent biofilm growth and maturation (i.e. the lowest 149 
 
concentration that resulted in no further increase in biofilm biomass after 4 h of 150 
adhesion). 151 
152 
153 
First, an overnight culture was diluted in Mueller Hinton Broth (MHB, Oxoid) to 
prepare an inoculum suspension containing appr. 108 cfu/mL. This suspension was 
added to the wells of a round-bottomed 96-well microtitre plate (TPP). Following 4 h 
of adhesion, the supernatant (containing non-adhered cells) was removed from all 
154 
155 
wells and the plates were rinsed with physiological saline (PS; 0.9% NaCl). Plate 156 
counts performed in preliminary experiments confirmed that following this 4 h period 157 
appr. 105 adhered cells are present in each well. Subsequently, 200 µL of antibiotic-158 
containing MHB (using identical antibiotic concentrations as in the MIC experiments) 159 
was added and plates were further incubated at 37°C. After 20 h of treatment, wells 160 
were again rinsed and finally 170 µL PS and 34 µL of a commercially available 
resazurin solution (CellTiter-Blue, CTB, Promega, Maddison, WI, USA) were added 
to all wells. Fluorescence was measured after 1 h incubation using a multilabel 
161 
162 
163 
microtitre plate reader (λex: 560 nm and λem: 590 nm). All MBIC experiments were 
performed in duplo. 
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Determination of the bactericidal effect of antibiotics on biofilms  167 
For all strains, the bactericidal effect of the antibiotics on cells present in biofilms, 168 
which were grown for 24 h (4 h of adhesion and 20 h of biofilm formation), was 
determined using antibiotic concentrations corresponding to 10 x MIC, except for 
169 
170 
tobramycin, for which a final concentration of 4 x MIC was tested. In addition, the 171 
bactericidal effect of tobramycin on sessile cells in older biofilms (grown for 76 h [4 h 172 
adhesion, 72 h growth] or 100 h [4 h adhesion, 96 h growth]) was also evaluated.  173 
 
Biofilms were grown on silicone discs (Q7-4735; Dow Corning, Midland, MI, USA) 174 
placed in the wells of a 24-well microtitre plate (TPP). Three discs were included per 175 
tested antibiotic and three untreated discs served as controls. Previous (unpublished) 176 
data from our own research group indicated that the number of cells present in the B. 177 
cepacia complex biofilms increased exponentially during appr. the first 16 h of biofilm 178 
development and remained constant afterwards. 179 
Starting from an overnight culture, an inoculum suspension containing appr. 108 180 
181 cfu/mL in MHB was prepared. Subsequently, 1 mL of this suspension was added to 
the wells. After 4 h of adhesion, all wells were rinsed three times using PS. Then, 182 
fresh sterile MHB was added and the biofilms were allowed to grow for an additional 183 
20 h period. After 4 h adhesion and 20 h biofilm formation, all discs were rinsed once 184 
and subsequently transferred to the wells of a microtitre plate containing antibiotics 185 
(in PS). After a 20 h treatment period, all discs were again rinsed and transferred to 186 
10 mL MHB. Sessile cells were removed from the discs by 3 cycles of vortexing (30s) 
and sonication (30s; Branson 3510, Branson Ultrasonics Corp, Danbury, CT, USA) 
and the number of cells was determined using conventional plate count methods.
187 
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189 23  
Older biofilms (76 h and 100 h) were grown and treated similarly; but an additional 190 
refreshment of medium was performed every 24 h. 191 
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Determination of the bactericidal effect of antibiotics on stationary phase 
planktonic cultures  
The bactericidal effect of all antibiotics on stationary phase planktonic cells was 
determined for each strain using antibiotic concentrations corresponding to 10 x MIC 
(or 4 x MIC for tobramycin). 
 
Starting from an overnight culture, an inoculum suspension containing appr. 108 198 
cfu/mL in MHB was prepared. This inoculum suspension was grown aerobically for 199 
24 h (stationary phase planktonic cultures) in a shaking warm water bath at 37°C. 200 
Subsequently, these cells were harvested by centrifugation, washed three times and 
diluted in PS until a suspension was obtained containing (per mL) twice the number 
201 
202 
of cfu present in the corresponding untreated biofilms. 500 µL of the latter 203 
suspension was added to 500 µL of double-concentrated antibiotic solutions (in PS). 204 
After 20 h of exposure to the antibiotics, the number of surviving cells in the treated 
and untreated planktonic cultures was determined using conventional plate count 
methods. 
205 
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Confocal laser scanning microscopy (CLSM) 209 
The effects of all antibiotics on B. cenocepacia LMG 16656 biofilm morfology were 210 
visualized using CLSM. To this end, 1 µl of Syto9 (λexc: 480 nm; λem: 500 nm; 211 
3.34mM in DMSO) and 1 µl of propidium jodide (λexc: 490 nm; λem: 635 nm; 20 mM in 212 
DMSO) (LIVE/DEAD BacLight bacterial viability kit L7012; Invitrogen, Carlsbad, CA, 213 
USA) were added to the biofilm supernatant. After a 15 min incubation period at room 214 
temperature, the biofilms were visualized with a Nikon C1 confocal laser scanning 215 
module attached to a motorized Nikon TE2000-E inverted microscope (Nikon 216 
Benelux, Brussels, Belgium) equipped with a Plan Apochromat 60.0x/1.20/0.22 water 217 
immersion objective.  218 
219 
220 
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Results 
MIC and MBIC experiments 
 
The results of the broth microdilution MIC tests are shown in Table 1. In general, the 222 
MICs observed for ciprofloxacin, tobramycin and trimethoprim-sulfamethoxazole 
varied widely, with MICs ranging from <0.25 mg/L to 128 mg/L, from 2 mg/L to 1024 
mg/L and from 0.25-4.75 mg/L to >128-2432 mg/L, respectively. The MICs for 
meropenem were between 0.5 mg/L and 32 mg/L, among the tested antibiotics 
223 
224 
225 
226 
representing the narrowest range. Meropenem, minocycline and ceftazidime were 
the most active antibiotics as only 39.5%, 15.8% and 39.5% of the tested strains, 
respectively, showed no growth-inhibition at breakpoint antibiotic concentrations. 
Although low concentrations of tobramycin (≤ 4 mg/L) were only able to inhibit growth 
of B. contaminans R-12710, high concentrations of tobramycin (> 256 mg/L) were 
active against 34 out of the 38 strains tested (89.5%). Among the antibiotics tested, 
227 
228 
229 
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232 
ciprofloxacin and trimethoprim-sulfamethoxazole had the lowest activity, as 47.4% 
and 76.3% of the tested strains continued growing in the presence of breakpoint 
concentrations of these antibiotics. 
233 
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239 
In general, the MICs observed for planktonic cells and the MBICs observed for 
freshly adhered (4 h) sessile cells were highly similar; only in 3.9% of the cases the 
MBICs showed more than a four fold difference compared to the corresponding MICs 
(data not shown). A scatter plot illustrating the high similarity between the minimal 
concentrations of ciprofloxacin necessary to prevent growth of planktonic and freshly 240 
adhered sessile cells is presented in Figure 1. Similar scatter plots were obtained for 
all other antibiotics (data not shown). 
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Determination of the bactericidal effect of antibiotics on stationary phase 
planktonic cultures and on biofilms 245 
 
The bactericidal effect of all antibiotics was determined on stationary phase 246 
planktonic cultures, which were grown for 24 h, as well as on 24 h old biofilms. In 247 
addition, the bactericidal effect of tobramycin on older planktonic cultures and 248 
biofilms (grown for 76 h or for 100 h) was also determined for three selected strains 249 
(B. multivorans LMG 18825, B. cenocepacia LMG 16656 and B. dolosa LMG 18943). 250 
In order to allow a comparison under similar conditions, the number of planktonic 251 
cells was adjusted to be equal to the number of sessile cells present in the 252 
corresponding biofilms.  253 
254 In general, the bactericidal effect of most antibiotics was comparable for all tested 
strains. Box plots representing an overview of the number of cfu/ (disc or mL) in the 255 
untreated controls and in the treated planktonic cultures and biofilms are shown in 256 
Figure 2. On average, less than a 90% reduction in the number of surviving cells was 257 
observed after treating planktonic cultures and biofilms with trimethoprim-258 
sulfamethoxazole, minocycline or ceftazidime. Among the tested antibiotics, 
tobramycin showed the highest bactericidal activity against planktonic B. cepacia 
complex cells, despite the fact that the tested concentrations were only four times 
higher than the corresponding MICs. In some cases, treatment with tobramycin even 
resulted in a total eradication of all planktonic cells. For 36 of the tested strains 
259 
260 
261 
262 
263 
(94.7%), tobramycin had the highest bactericidal activity of the tested antibiotics 264 
against sessile cells. CLSM images of untreated and ceftazidime-, ciprofloxacine-, 265 
meropenem-, minocycline- and trimethoprim-sulfamethoxazole-treated B. 266 
cenocepacia LMG 16656 biofilms revealed that no changes in biofilm morphology 267 
were induced by the latter treatments (Figure 3A and 3B and data not shown). The 268 
large reductions in cells numbers following a treatment with tobramycin were also 269 
confirmed (Figure 3C).  270 
 
For the majority of antibiotics tested, the fraction of surviving planktonic and sessile 271 
cells was similar (representative results for two strains are shown in Figure 4); after 272 
treatment with ciprofloxacin, minocycline or trimethoprim-sulfamethoxazole, the 
fraction of surviving sessile and planktonic cells showed less than a 10-fold 
difference for all strains. Treatment with ceftazidime or meropenem led to more than 
a 10-fold difference in reduction between planktonic cultures and biofilms for 3 (7.9%) 
273 
274 
275 
276 
and 6 (15.8%) strains, respectively. For 24 of the strains tested (63.2%), the fraction 277 
of sessile cells surviving a tobramycin treatment showed more than a 10-fold 278 
difference compared to the fraction of surviving planktonic cells.  279 
Treatments with tobramycin on older biofilms and on older planktonic cultures 280 
resulted in similar reductions as seen for the biofilms and the stationary phase 281 
planktonic cultures that were grown for only 24 h (Figure 5). 282 
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Discussion 
Antibiotic resistance is considered an important virulence factor of B. cepacia 
complex organisms. 1 Although therapy is usually guided by antimicrobial 
susceptibility testing, eradication of B. cepacia complex organisms is rarely achieved. 
24 Multiple hypotheses have been formulated to explain this failure, including 
inadequate antibiotic concentrations or inactivation of the antibiotic in sputum, 
impaired host defences in CF patients, biofilm formation, ‘inoculum’ effect and in vivo 
growth rate of these organisms. 18 In the present study, we have focussed on the 
growth inhibitory and bactericidal effects of ceftazidime, ciprofloxacin, meropenem, 
minocycline, tobramycin and trimethoprim-sulfamethoxazole on 38 B. cepacia 
complex strains belonging to 17 species. 
293 
294 
295  
 
Growth inhibitory concentration of antibiotics for exponentially growing 296 
planktonic cultures and for freshly adhered sessile cells 297 
298 
299 
300 
301 
302 
In general, our results confirm the previously reported high intrinsic resistance of B. 
cepacia complex strains against a broad variety of antibiotics. 8,12,13 Meropenem, 
minocycline and ceftazidime showed the best growth inhibitory activity at clinically 
relevant concentrations. Although B. cepacia complex organisms are typically 
resistant against aminoglycosides, 9 high doses of tobramycin inhibited the majority 
of tested strains. Nebulized tobramycin yielding high peak concentrations in sputum, 
are increasingly used for treating CF patients. 
303 
304 
305 
17,25,26 Consequently, these higher 
concentrations should be taken into account when evaluating the usefulness of this 
antibiotic. Several reports confirm that nebulized tobramycin shows great promise in 306 
the treatment of B. cepacia complex infected CF patients: for example, Middleton et 307 
al. recently described the complete eradication of B. cepacia complex organisms 
from the lungs of CF patients by using a combination of nebulized tobramycin and 
amiloride. 24
308 
309 
310 
311 
 In addition, a combination therapy with nebulized and intravenous 
meropenem and tobramycin also resulted in the successful treatment of a female CF-
patient suffering from cepacia syndrome, although the sputum samples of the latter 312 
patient remained positive for B. cenocepacia. 27 313 
314 
315 
Multiple studies have reported a decreased susceptibility to certain antibiotics (e.g. 
meropenem, ceftazidime) of P. aeruginosa and B. cepacia complex isolates grown as 
biofilms. 28-31 However, the results of the present study indicate that the growth 316 
inhibitory concentrations for exponentially growing B. cepacia complex planktonic 
cells and for freshly adhered sessile cells are similar. This discrepancy between our 
results and those from previous studies may be due to pronounced differences in 
experimental approach. For example, some studies compared the bacteriostatic 
317 
318 
319 
320 
 
activity of antibiotics against planktonic and dispersed cells with the bactericidal 
activity against sessile cells (Minimal Biofilm Eradication Concentration; MBEC). 
321 
322 30,31 
Other studies compared the minimal growth inhibitory concentrations of antibiotics on 323 
actively growing planktonic cultures with biofilm inhibitory concentrations (BICs) 324 
obtained after treating 20 h-old biofilms. 28,29 Yet, in order to allow a correct 325 
comparison between the susceptibility of planktonic and sessile B. cepacia complex 326 
cells, experimental conditions (including growth phase) should be identical. In fact, 
previous research on a B. cepacia strain revealed a dramatic decrease in 
327 
328 
susceptibility for ceftazidime and ciprofloxacin during the progression of the 
exponential growth phase. An increase of the resistance was observed for both 
planktonic cultures and biofilms of this strain during the later stages of the 
exponential growth phase, compared to the earlier stages of exponential growth.
329 
330 
331 
332  18 
Consequently, in the present study, we aimed to compare the growth inhibitory 333 
effects of antibiotics against planktonic and sessile B. cepacia complex cells under 334 
similar experimental conditions. 335 
336  
Bactericidal effect of antibiotics on stationary phase planktonic cultures and 337 
on biofilms 338 
339 
340 
The bactericidal effect of all antibiotics, at a concentration of 10 x MIC (4 x MIC for 
tobramycin), was evaluated for planktonic cultures grown for 24 h as well as for 
biofilms obtained after 24 h (4 h of adhesion and 20 h of biofilm formation). 341 
Trimethoprim-sulfamethoxazole and minocycline, both bacteriostatic agents, yielded 
the lowest reductions in cell numbers under these test conditions. Tobramycin had 
the highest bactericidal effect among the antibiotics tested: on average reductions of 
342 
343 
344 
 
345 
346 
347 
more than 99.999% and 99.98% were observed when treating planktonic cultures 
and biofilms, respectively.  
For the majority of strains, treatment with ceftazidime, ciprofloxacin, meropenem, 
minocycline or trimethoprim-sulfamethoxazole yielded similar reductions in the 348 
number of planktonic and sessile cells. In addition, CLSM images revealed that no 349 
changes in biofilm morphology were induced by the latter treatments. Treatment with 
tobramycin mostly resulted in a higher reduction in the number of planktonic cells 
compared to that observed in biofilms; yet, for some strains, including B. dolosa and 
B. anthina strains, similar reductions were observed under both conditions.  
350 
351 
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357 
358 
359 
360 
361 
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363 
364 
365 
Previously, Spoering and Lewis reported similar bactericidal activity of carbenicillin, 
ofloxacin and tobramycin on sessile and planktonic P. aeruginosa PAO1 cells. 17 
They concluded that the general assumption about sessile cells showing an 
increased tolerance against antibiotics relative to stationary-phase planktonic 
cultures is unwarranted. The minor differences in reductions in the antibiotic-treated 
planktonic cultures and biofilms observed for the large majority of B. cepacia complex 
strains in the present study are in agreement with their observations. Yet, unlike their 
observations for P. aeruginosa PAO1, we did observe a decreased susceptibility of 
sessile cells towards tobramycin for multiple B. cepacia complex strains.  This 
decreased susceptibility could be due to binding of the cationic tobramycin to biofilm 
components, resulting in retarded penetration. Yet, other biofilm specific factors may 
also play a role. 32 
In order to evaluate a possible increase in resistance towards tobramycin in older 366 
biofilms and planktonic cultures compared to their younger counterparts, we also 367 
determined the bactericidal effect of tobramycin on biofilms and planktonic cultures 368 
grown for 76 h and 100 h. In previous studies on the susceptibility of P. aeruginosa 369 
 
biofilms, an increased resistance of older biofilms against this antibiotic was 370 
reported.33 Yet, in the present study no meaningful differences in susceptibility 371 
between the older biofilms and planktonic cultures, on the one hand, and their 372 
younger counterparts, on the other hand, were observed (Figure 5). A possible 373 
explanation for this unexpected result may lie in the differences of the used growth 374 
conditions and consequently, in the differences in observed growth patterns. Unlike 375 
in some previous studies, cell numbers did not increase further in the older B. 376 
cepacia complex biofilms compared to the younger biofilms (grown after 24 h). 33, 34 377 
In fact, the impact of these variations in growth pattern, which are the result of 378 
differences in nutritional limitations, can influence greatly the susceptibility to 379 
antibiotics. 35  380 
381  
In conclusion, under the conditions used in the present study, our results show 
similar bacteriostatic activities of the antibiotics tested against exponentially growing 
planktonic B. cepacia complex cells and freshly adhered sessile cells. In addition, 
382 
383 
384 
similar bactericidal activities were observed against planktonic cultures and biofilms 385 
for the majority of antibiotics tested. The results of the present study support the 
hypothesis that the selection of antibiotics for the treatment of B. cepacia complex 
infected CF patients should not only be based on conventional culturing techniques 
for planktonic cells. In fact, the lack of correlation between the conventional in vitro 
susceptibility tests and the clinical response caused by these antibiotics in vivo, 
suggests that other methods focussing on the bactericidal effect of antibiotics against 
stationary phase planktonic cells or biofilms may provide a better alternative for 
clinicians to select the best possible treatment. 
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 Table1: MIC of six antibiotics for 38 B. cepacia complex strains and two control 
strains.  
Strain 
MIC (mg/L) 
CAZ 
(8a) 
CIP 
(1a) 
MEM 
(4a) 
MIN 
(4a) 
TOB  
(4a or 256b)
SXT 
(2-38a) 
B. cepacia LMG 18821 64 16 16 16 512 8-152 
B. cepacia LMG 1222T 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 1 8 2 32 8-152 
B. multivorans LMG 18822 32 4 16 4 128 16-304 
B. multivorans LMG 18825 4 4 8 1 128 8-152 
B. multivorans LMG 13010T 4 4 4 2 64 4-76 
B. multivorans LMG 17588 4 1 4 2 64 8-152 
B. cenocepacia LMG 16656T 128 8 32 16 256 >128-2432 
B. cenocepacia LMG 18828 32 128 8 4 256 128-2432 
B. cenocepacia LMG 18829 8 4 4 8 128 32-608 
B. cenocepacia LMG 18830 8 16 4 1 1024 8-152 
B. stabilis LMG 14294T 8 32 4 1 128 >128-2432 
B. stabilis LMG 14086 4 0,5 2 1 32 2-38 
B. vietnamiensis LMG 18835 4 1 2 2 64 8-152 
B. vietnamiensis LMG 10929T 4 1 1 1 16 8-152 
B. dolosa LMG 18943T >128 64 32 4 128 32-608 
B. dolosa LMG 18941 32 64 8 4 256 16-304 
B. ambifaria LMG 19182T 4 <0.25 2 1 16 2-38 
B. ambifaria LMG 19467 2 2 2 2 128 4-76 
B. anthina LMG 20980T 2 <0.25 1 <0.25 16 4-76 
B. anthina LMG 20983 4 <0.25 2 <0.25 32 1-19 
B. pyrrocinia LMG 14191T 16 1 8 2 64 8-152 
B. pyrrocinia LMG 21824 16 2 4 4 512 8-152 
B. ubonensis LMG 20358T 4 1 8 2 64 4-76 
B. ubonensis LMG 24263 8 1 16 2 64 2-38 
B. latens LMG 24064T 4 4 2 4 32 8-152 
B. latens R-11768 16 8 16 8 512 16-304 
B. diffusa LMG 24065T 32 2 4 1 128 4-76 
B. diffusa LMG 24266 32 2 4 1 64 4-76 
B. arboris LMG 24066T 4 1 2 2 64 1-19 
B. arboris R-132 8 <0.25 8 <0.25 128 1-19 
B. seminalis LMG 24067T 8 2 4 16 128 4-76 
B. seminalis LMG 24272 4 1 2 2 64 8-152 
B. metallica LMG 24068T 32 0.5 8 4 64 4-76 
B. metallica R-2712 16 0.5 8 2 64 2-38 
B. lata LMG 6992 2 0.25 0.5 0.5 32 0.25-4.75 
B. lata R-9940 2 0.25 1 1 16 2-38 
B. contaminans LMG 16227 16 1 4 8 32 8-152 
B. contaminans R-12710 8 0.25 2 1 2 4-76 
P. aeruginosa ATCC 27853 2 0.5 0.5 - 0.5 16-304 
E. coli ATCC 25922 0.25 0.008 0.016 0.5 0.5 ≤0.5-9.5 
a Breakpoint concentrations CLSI guidelines non-Enterobacteriaceae 514 
 
 515 
516 
517 
518 
519 
520 
521 
b Breakpoint for high concentrations of tobramycin achieved by nebulization 
CAZ: ceftazidime; CIP: ciprofloxacin; MEM: meropenem; MIN: minocycline; TOB: 
tobramycin; SXT: trimethoprim-sulfamethoxazole (1-19) 
 
Figure 1: Scatter plot of the minimal concentrations of ciprofloxacin necessary to 
inhibit growth of planktonic cultures (MIC) and freshly adhered sessile cells (4 h, 
MBIC) of the 38 tested B. cepacia complex strains.  
Figure 2: Boxplot illustrating the distribution of the number of cfu/ (disc or mL) 522 
recovered from the untreated and treated planktonic cultures (white) and biofilms 523 
(grey) for all 38 tested B. cepacia complex strains. 524 
UC: untreated control; CAZ: ceftazidime; CIP: ciprofloxacin; MEM: meropenem; MIN: 525 
minocycline; TOB: tobramycin; SXT: trimethoprim-sulfamethoxazole (1-19) 526 
Figure 3: Representative images of 24 h old B. cenocepacia LMG 16656 biofilms, 527 
which were treated with saline (A), ciprofloxacin (80 mg/L; B) or tobramycin (1024 528 
mg/L; C) during 20 h. The scale bar represents 20 µm. 529 
Figure 4: Average numbers of cells (log) present in treated and untreated B. 530 
multivorans LMG 18825 and B. cenocepacia LMG 16656 planktonic cultures (white 531 
bars) and biofilms (grey bars). Error bars represent standard deviations. 532 
UC: untreated control; CAZ: ceftazidime; CIP: ciprofloxacin; MEM: meropenem; MIN: 533 
minocycline; TOB: tobramycin; SXT: trimethoprim-sulfamethoxazole (1-19) 534 
Figure 5: Average numbers of cells (log) present in untreated and tobramycin treated 535 
B. multivorans LMG 18825, B. cenocepacia LMG 16656 and B. dolosa LMG 18943 536 
planktonic cultures (untreated: black bars; treated: white bars) and biofilms 537 
(untreated: shaded bars; treated: grey bars) which were first grown for 24 h, 76 h or 538 
100 h. Error bars represent standard deviations. 539 
